<DOC>
	<DOC>NCT02657785</DOC>
	<brief_summary>This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.</brief_summary>
	<brief_title>Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy</brief_title>
	<detailed_description>The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Inclusion criteria: Newly diagnosed histologically proven nonHodgkin's lymphoma (NHL). Exclusion criteria: Involved sites other than the brain, meninges, CSF, or the eyes. Age less than 18 years or greater than 75 years. Inadequate bone marrow capacity (defined as neutrophils&lt;1.5 ×10^9/L, platelets &lt;100 ×10^9/L, and hemoglobin level&lt; 8 g/dL). Known cause of immunosuppression (ie, HIV type I infection). Any previous malignancy. Creatinine clearance below 60 mL/min. Heart insufficiency (NYHA IIIB or IV). Uncontrolled infection. Noncompensated active pulmonary or liver disease. Previously treated for PCNSL, except by corticosteroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>